Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-11-18 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release issued by Onxeo announcing a new strategic research collaboration for its oncology assets. It does not contain financial statements, audit results, or regulatory filings, nor is it a report publication announcement. It is a corporate announcement regarding business strategy and R&D partnerships, which falls under the general regulatory announcement category (RNS) as it does not fit into more specific categories like M&A or capital updates. FY 2015
2015-11-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated November 9, 2015, announcing 'Premiers résultats positifs de l'essai de Phase 1 de belinostat' (First positive results from the Phase 1 trial of belinostat). It details clinical trial efficacy (89% objective response rate) and tolerability, and explicitly states that the full data will be presented orally at the American Society of Hematology (ASH) annual conference. This content focuses on announcing key financial/clinical results for a specific period (Phase 1 trial outcome) rather than being the full annual report (10-K), a comprehensive interim report (IR), or a transcript of a call (CT). It fits the definition of an initial announcement of periodical/key financial/clinical results, which aligns best with the Earnings Release (ER) category, even though the results are clinical rather than purely financial earnings. Since it is a formal announcement of key results, ER is the most appropriate fit among the options provided, as it is not a presentation (IP) or a management discussion (MDA). FY 2015
2015-11-09 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "CORRIGE ET REMPLACE : Onxeo : Information trimestrielle au 30 septembre 2015" and explicitly states it announces "les principales avancées opérationnelles et le chiffre d'affaires consolidé du 3 trimestre 2015." It provides detailed financial figures (revenue, cash position) and operational updates for a specific interim period (Q3 2015). This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is a correction, the core nature of the filing remains the quarterly report itself, not just an announcement of its publication (RPA) or a general regulatory filing (RNS). The length (9123 chars) is substantial, further supporting classification as the report content rather than a brief announcement. Q3 2015
2015-11-06 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is a quarterly financial update from Onxeo SA for the period ending September 30, 2015. It provides consolidated revenue figures, operational highlights, and cash position details. While it contains financial data, it is structured as a press release announcing quarterly results rather than a full, formal interim financial report (which would typically be a longer, audited or reviewed regulatory filing). According to the classification guidelines, this fits the 'Earnings Release' (ER) category as it is the initial announcement of quarterly financial results. Q3 2015
2015-11-05 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is titled "Onxeo Reports Third Quarter 2015 Business Update" and explicitly states it "published an update on major milestones achieved during the third quarter of 2015 as well as its consolidated revenues for the period ending September 30, 2015." It provides key financial figures (€1.1 million in Q3 revenue, €2.7 million for the first nine months) and operational updates. This structure—a press release summarizing period-specific financial results and operational highlights without being the full, detailed statutory report—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), but rather the initial announcement of those results. Q3 2015
2015-11-05 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a short press release announcing Onxeo's participation in upcoming investor conferences and meetings (e.g., Société Générale Biotech & Medtech CEO conference, JP Morgan Healthcare Conference). It details the dates and locations where management will present company achievements and strategy to investors. This type of announcement, which informs the market about management's schedule for engaging with investors, is best classified as an Investor Presentation (IP) announcement or related material, although the document itself is an announcement *about* future presentations rather than the presentation slides themselves. Given the options, 'Investor Presentation' (IP) is the closest fit as it relates directly to management's scheduled interactions with investors to discuss strategy and financials. However, since this is an announcement of *attendance* at events, and not the presentation material itself, it could also be considered a general Regulatory Filing (RNS) or potentially related to Management Reports (MDA) if it were a detailed outlook. Given the focus on scheduled investor meetings, IP is the most specific category related to investor engagement activities.
2015-10-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.